Tag Archive for CJC-1295 DAC

CJC-1295 DAC

CJC-1295 DAC

CJC-1295 DAC has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC – 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.

is a long acting Growth Hormone Releasing Hormone, which causes the anterior pituitary to release more growth hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).

CJC-1295 DAC vs. CJC-1295 No DAC

CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse of Human Growth Hormone.

ConjuChem and The Development of CJC-1295 DAC

CJC-1295 DAC is a tetra substituted peptide analogue of Growth Hormone Releasing Hormones with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. A Canadian biotechnology company called ConjuChem had invented CJC-1295. Clinical Research on CJC-1295 first began during the mid-2000s. The goal of the peptide, acting to raise hgh like Ipamorelin, was to treat visceral fat deposits in obese AIDS patients because it is presumed that increased levels of exogenous hGH increase fat loss, or lipolysis. In one study, results showed that the measured GH release in rats over a two hour period showed that CJC-1295 released twice as much GH as CJC-1293 DAC. This result makes it preferable for immediate effectiveness as a result of the longer peak. With the use of a Growth Hormone Releasing Peptide (GHRP), such as Growth Hormone Releasing Hexapeptide (GHRP-6) in conjunction with CJC-1295 DAC, a study has shown that the GHRP’s create a Growth Hormone pulse which helps the CJC-1295 work effectively. Clinical research’s involving CJC-1295 have shown that it had been successful for most research subjects..

More Peptide Info

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit

Bodybuilding peptide CJC-1295 DAC Drug Affinity Complex

CJC-1295 DAC

CJC-1295 DAC is a GHRH (Growth Hormone Releasing Hormone) with Drug Affinity Complex (DAC) and stimulates growth hormone release from the pituitary. CJC-1295 DAC’s interesting point is a result of the addition of DAC which lengthens the drugs active life. The DAC makes the drug a long-acting version of GHRH with an extended half life of approximately 8 days. For research purposes it can be used much more conveniently then other GHRH’s. Therefore only 1 or 2 weekly injections are needed for constant elevated levels of HGH and IGF-1 in the research subject.

Researchers get all the same benefits of other short acting GHRH’s and HGH but in a much more convenient manner. HGH may cause bigger spikes in GH but with CJC-1295 DAC you get continuous surges in GH throughout the day and elevated IGF-1 levels lasting for up to 28 days post injection. Teichman SL et al. (2006) displayed after multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 days. Interestingly they shown after a single injection of CJC-1295 DAC, there were dose-dependent increases in mean plasma GH concentrations by 2 to 10 fold for 6 days. In addition to increases in mean plasma IGF-I concentrations by 1.5 to 3 fold for 9–11 days.

Numerous studies I have read on this peptide continually display it’s incredible ability to increase GH and IGF-1. It’s a very interesting peptide for all researchers due to it’s possible medical benefits. Short-term GHRH infusions enhance GH pulsatility and increase IGF-I, but the short life GHRH’s have limited therapeutic use. Ionescu M et al. (2006) also shown CJC-1295 DAC increasing trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The long acting nature of this peptide opens the door to many possibilities in the medical field. Moreover no serious adverse reactions have been reported in my own or any of the studies I have read. This would lead me to believe this is a safe peptide for research purposes and carries no risks. The only side effect I have come across in the studies published is a strong head rush experienced by patients after injection.

Research has shown CJC-1295 DAC stimulates slow wave sleep (SWS). SWS is a deep sleep and consists of stages 3 and 4 of non-rapid eye movement. These stages are the ones most important to the bodies repair and recovery. They are also important to consolidate new memories.

The advantage of using CJC-1295 DAC over actual HGH injections is that the later shuts down the body’s own natural production of GH. CJC-1295- DAC only stimulates the bodies own GH production so the body will not struggle to produce it’s own GH after usage. In the long run I feel future studies will highlight the importance of this in relation to health. Moreover on the black market good GH is getting near on impossible to find on a consistent basis.

To make the most of CJC-1295 DAC during research experiments, somatostatin needs to be controlled as it inhibits GH release. The best way to do this is using a compound known as an acetylcholineesterase inhibitor. From reading various research studies I would recommend Huperzine-A. This is being used by many researchers to boost the effectiveness of CJC-1295-DAC. Many researchers also add Green tea to their protocol as the ECGC’s in green tea increase the inhibitory effectiveness of Huperzine-A a on acetylcholineesterase. Zhang L et al. (2009) investigated EGCG’s enhancement effect of Huperzine A on inhibiting acetylcholinesterase (AChE). The inhibitory effect of huperzine A on acetylcholinesterase is quite weak in the whole phase. EGCG hardly inhibits the AChE activity within the range 10-300 mg/kg. However, upon addition of EGCG to the huperzine A groups, a remarkably enhanced inhibitory effect was observed. Although I must add I have taken CJC-DAC alone a few times and the results were fantastic every time.

If a researcher was solely concerned with increasing a patients GH and IGF-1 levels I would recommend including a GHRP to the CJC-1295 DAC. For the highest spike in GH I would utilize GHRP-2 in addition with an acetylcholineesterase inhibitor. One researcher took the advice about inhibiting acetylcholinesterase during a research study of his own. CJC-1295 DAC was used at 3mg per week combined with ghrp2 at 100mcg 4 times per day. He also used the short acting CJC-1295 during his study. His serum gh was 48 and IGF-1 tested at 390. These sort of numbers display the power of these GHRH and GHRP’s combined.

I have conducted my own research using CJC-1295 DAC and can safely state it is the most effective peptide I have observed so far. Even as little as 2mg weekly with no added GHRP brings about significant fatloss, improved sleep, better skin and general mood lift to my research subject. However for the best bang for your buck I highly recommend adding in ghrp-2. Other GHRP’s are fantastic but I generally feel GHRP-2 is most effective. In conclusion CJC-1295 DAC seems to be a very safe and extremely effective peptide. It’s long active length provides numerous benefits over other GHRH’s. I have observed no bad side effects and look forward to seeing many future studies showing the benefits I have seen it bring

article sent in by an avid reader

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit
eXTReMe Tracker